Randomised, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma in an Australian cohort.

The article presents the discussion on Melasma being a complex and therapeutically challenging condition for dermatologists globally. Topics include two randomised controlled trials (RCT) showing significant improvement in melasma after 12 weeks treatment with 250 mg oral TA; and exclusion criteria included contraindications to TA from the US Food and Drug Administration and Monthly Index of Medical Specialities, Australia.